



Vaccines and Global Health: The Week in Review
20 June 2020 :: Number 556
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)



Milestones :: Perspectives :: Research

.....
.....

Pneumonia vaccine price drops dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment

New supply agreement between UNICEF and Serum Institute of India (SII) makes pneumococcal conjugate vaccine (PCV) available at US\$2.00 per dose, a 43 per cent reduction from the Gavi price at the start of the Advance Market Commitment

Geneva/ New York, 16 June 2020 – Lower-income countries across the world will now be able to access life-saving pneumococcal conjugate vaccines, which protect against the leading cause of pneumonia, for US\$ 2 per dose, thanks to a new supply agreement between UNICEF, Gavi's procurement partner, and the Serum Institute of India (SII). The new price represents a 43 per cent reduction from the [Gavi price of US\\$3.50](#) at the start of the Advance Market Commitment (AMC).

The [supply agreement](#) is the eighth to take place under the Vaccine Alliance's Advance Market Commitment (AMC) mechanism, and the first to include a developing country manufacturer. Under the agreement, the Indian manufacturer will provide ten million PCV doses to Gavi-supported countries each year for the next ten years. The pneumococcus bacterium is the leading cause of severe pneumonia and is a major cause of morbidity and mortality worldwide. Most of these deaths occur in lower-income countries and include a disproportionate number of children under the age of two.

The AMC, which is set to end this year, was launched by Gavi in 2009 – with the support of donors Italy, the United Kingdom, Canada, Russia, Norway and the Bill & Melinda Gates Foundation – to solve a clear example of market failure: complex vaccines like PCV would normally reach low-income countries, where the disease burden is often highest, ten to 15 years after their introduction in industrialised countries. The AMC mechanism incentivised research and development (R&D), particularly for vaccines suitable for developing country epidemiological contexts, and an expansion in manufacturing capacity to meet demand from lower-income countries while maintaining an affordable price per dose...

.....
.....

Covid-19 Impacts

World Bank [to 20 June 2020]

<http://www.worldbank.org/en/news/all>

[We generally limit coverage to regional and global level initiatives, recognizing that a number of country-level announcements are added each week]

COVID 19: Debt Service Suspension Initiative

This webpage provides a detailed country-by-country breakdown of DSSI participants and the amounts they owe to the creditors. The data will be updated regularly. Overview In April, the World Bank's Development...

Date: June 19, 2020 Type: Brief

Simulating the Potential Impacts of the COVID-19 School Closures and Learning Outcomes: A set of Global Estimates

School closures due to COVID-19 have left over a billion students out of school. Governments are pursuing a variety of approaches to mitigate school closures. At the same time, all countries are undergoing...

Date: June 18, 2020 Type: Publication

COVID-19 Could Lead to Permanent Loss in Learning and Trillions of Dollars in Lost Earnings

WASHINGTON, June 18, 2020—School closures due to COVID-19 have left most students on the planet out of school – 1.6 billion students at the peak in April 2020. This global shock to all education...

.....
.....

Featured Journal Content

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

Research Article

Vaccination as a social contract

Lars Korn [lars.korn@uni-erfurt.de], Robert Böhm, Nicolas W. Meier, and Cornelia Betsch
PNAS first published June 15, 2020. <https://doi.org/10.1073/pnas.1919666117>

Significance

Vaccines support controlling and eliminating infectious diseases. As most vaccines protect both vaccinated individuals and the society, vaccination is a prosocial act. Its success relies on a large number of contributing individuals. We study whether vaccination is a social contract where individuals reciprocate and reward others who comply with the contract and punish those who don't. Four preregistered experiments demonstrate that vaccinated individuals indeed show less generosity toward nonvaccinated individuals who violate the social contract. This effect is independent of whether the individuals are members of the same or different social groups. Thus, individuals' behavior follows the rules of a social contract, which provides a valuable basis for future interventions aiming at increasing vaccine uptake by emphasizing this social contract.

Abstract

Most vaccines protect both the vaccinated individual and the society by reducing the transmission of infectious diseases. In order to eliminate infectious diseases, individuals need to consider social welfare beyond mere self-interest—regardless of ethnic, religious, or national group borders. It has therefore been proposed that vaccination poses a social contract in which individuals are morally obliged to get vaccinated. However, little is known about whether individuals indeed act upon this social contract. If so, vaccinated individuals should reciprocate by being more generous to a vaccinated other. On the contrary, if the other doesn't vaccinate

and violates the social contract, generosity should decline. Three preregistered experiments investigated how a person's own vaccination behavior, others' vaccination behavior, and others' group membership influenced a person's generosity toward respective others. The experiments consistently showed that especially compliant (i.e., vaccinated) individuals showed less generosity toward nonvaccinated individuals. This effect was independent of the others' group membership, suggesting an unconditional moral principle. An internal metaanalysis ($n = 1,032$) confirmed the overall social contract effect. In a fourth experiment ($n = 1,212$), this pattern was especially pronounced among vaccinated individuals who perceived vaccination as a moral obligation. It is concluded that vaccination is a social contract in which cooperation is the morally right choice. Individuals act upon the social contract, and more so the stronger they perceive it as a moral obligation. Emphasizing the social contract could be a promising intervention to increase vaccine uptake, prevent free riding, and, eventually, support the elimination of infectious diseases.

.....
.....

Featured Journal Content

The Lancet

Jun 20, 2020 Volume 395 Number 10241 p1883-1948, e107-e111

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Global governance for COVID-19 vaccines

The Lancet

The COVID-19 pandemic has uncovered serious gaps in the health-care systems of many nations. In particular, it exposes a fragmented global governance system that does not have the structures to coordinate the pooling and sharing of resources needed to combat pandemics. Since the early days of the pandemic, medical protectionism has emerged as nations scrambled for their own stocks of personal protective equipment and ventilators. COVID-19 vaccines could be the next example. Already there is a danger of a vaccine bidding war, with governments competing for a limited number of doses, well before a vaccine even reaches the market.

Enormous amounts of public money and resources poured into vaccine research and development have resulted in more than 150 COVID-19 vaccine candidates, ten of which are now in clinical trials. The most advanced candidate is AZD1222, first developed by researchers at the University of Oxford with public and philanthropic funds from CEPI and subsequently licensed to AstraZeneca. Last month, the UK Government boosted its national vaccine programme with £65·5 million towards AZD1222. In return, 30 million doses will be reserved for people in the UK by September, as part of an agreement to deliver 100 million doses in total. The US Government too set aside US\$1·2 billion to secure 300 million doses of the same vaccine for use in the USA as part of the national programme Operation Warp Speed to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures. But neither a nationalist nor a free-market-driven approach will lead to equal access to vaccines.

In June, France, Germany, Italy, and the Netherlands formed the Inclusive Vaccine Alliance to persuade pharmaceutical companies to make COVID-19 vaccines accessible and affordable to

EU member states. A portion of vaccines will be made available to low-income countries, including in Africa; yet how big this portion will be, which countries will benefit from it, and who will make these decisions are less clear. Many middle-income countries might be left out.

Political leaders, including Emmanuel Macron, Angela Merkel, and Xi Jinping, have rightly called for COVID-19 vaccines to be a global public good—a people's vaccine, available to all. At the Global Vaccine Summit on June 4, world leaders including those from the UK, Germany, and Canada, together with the Bill & Melinda Gates Foundation, pledged \$750 million to AstraZeneca for 300 million doses of AZD1222 on a no-profit basis, as part of the Gavi Covax Advance Market Commitment. The Serum Institute of India will also produce up to 1 billion doses for low-income and middle-income countries. Covax's initial aim is to raise \$2 billion to accelerate the manufacture of a COVID-19 vaccine on a huge scale and to distribute it according to need, rather than ability to pay.

This commitment is commendable. It delivers a powerful message to governments and vaccine developers that if legally binding, solid measures are put in place, and money pledged, vaccines can be made available and affordable universally. However, many big questions remain. Have the funders agreed to equitable access? How will the vaccines be priced? Will governments commit to sharing vaccines according to fair allocation rules being developed by WHO? Can technology be transferred royalty-free to multiple manufacturers? "The question of who will get priority access to vaccines is core to the global public interest, we need to get the governance of these decisions right, otherwise there will be tremendous resentment and unnecessary deaths, not to mention decreased capacity to get this pandemic under control", Suerie Moon, co-director of the Global Health Centre at The Graduate Institute (Geneva, Switzerland), told The Lancet. Transparency in such decisions is fundamental.

There is a urgent need for new arrangements at the global level to facilitate the development, finance, production, and equitable distribution of COVID-19 vaccines. Controlling the pandemic demands global cooperation. The nationalist and competitive approaches taken by a few high-income countries to get hold of a small supply of vaccines could result in excessive casualties in other parts of the world. Global solidarity is needed instead, and resources must be pooled and shared. Gavi Covax is a step in the right direction.

It is imperative that more governments and pharmaceutical companies agree to shoulder the costs of vaccine research and manufacturing, and to share data and technologies. They need to commit to WHO allocation guidelines and cooperate globally to distribute vaccines fairly to those at greatest risk. A pandemic vaccine needs strong global governance behind it.

.....
.....

International regulators stress value of safe and effective vaccines

EMA Press release

18/06/2020

EMA has endorsed two statements about the importance, safety and effectiveness of vaccines published today by the International Coalition of Medicines Regulatory Authorities (ICMRA). International regulators from around the world have come together and jointly developed these statements for healthcare professionals and the general public to give assurance that the

regulatory processes for the authorisation and safety monitoring of vaccines are robust, independent and focus firmly on public health.

'The COVID-19 health emergency reminds us how important vaccines are to protect ourselves and our loved ones against infectious diseases,' said Guido Rasi, Chair of ICMRA and EMA's Executive Director. 'In fact, vaccines are that one medical intervention that benefits not only those who receive it directly but also those who are too young, too old or too ill to be vaccinated themselves.'

The two ICMRA statements aim to reassure healthcare professionals and the public around the globe that medicines regulators only allow vaccines onto the market that fulfil the highest standards of safety, efficacy and quality.

In recent years, vaccination coverage has dropped to sometimes dangerously low levels in some countries, which increases the risk of the disease spreading and affecting the unvaccinated. The ICMRA statements reiterate that it is everyone's responsibility to get vaccinated in order to protect not only themselves but also their friends, communities, vulnerable populations who cannot get immunised as well as the generations to come.

ICMRA is an international coalition of 29 medicines regulatory authorities from every region in the world, with WHO as an observer, which works to address global regulatory challenges. Medicines regulators recognise their important role in facilitating access to safe and effective high-quality medicines that are essential to human health and well-being. This includes ensuring that the benefits of vaccines outweigh their risks.

The development of the joint statements followed a series of discussions among ICMRA members on new ways to collaborate and enhance confidence in vaccine safety and effectiveness...

Date: June 18, 2020 Type: Press Release

.....
.....

EMERGENCIES

Coronavirus [COVID-19]

Public Health Emergency of International Concern (PHEIC)

The Guardian, Sat 20 Jun 2020 08.42 EDT Last modified on Sat 20 Jun 2020 16.18
Coronavirus outbreak

'The pandemic is accelerating': WHO warns of dangerous coronavirus phase – video

The World Health Organization has announced the coronavirus pandemic is accelerating and more than 150,000 cases of Covid-19 were reported in one day on Thursday, the highest single-day number so far.

Tedros Adhanom Ghebreyesus, the WHO director general, told reporters in Geneva refugees were particularly at risk from the pandemic and that nearly half of the newly reported cases were in the Americas, with significant numbers from South Asia and the Middle East.

[Video: 02:03]

.....

WHO - [Situation report - 152](#)

Coronavirus disease 2019 (COVID-19) 20 June 2020

Confirmed cases :: 8 525 042

Confirmed deaths :: 456 973

Countries, areas or territories with cases :: 216

Highlights

WHO Director-General Dr Tedros, in his regular media briefing yesterday, highlighted that today is World Refugee Day and highlighted the risks of COVID-19 for some of the world's most vulnerable people. He also stressed the shared duty to do everything we can to prevent, detect and respond to transmission of COVID-19 among refugee populations.

WHO has published 'Criteria for releasing COVID-19 patients from isolation' which provides an update to previous guidance. The updated criteria reflect recent findings that patients whose symptoms have resolved may still test positive for the COVID-19 virus for many weeks. Despite this positive test result, these patients are not likely to be infectious and therefore are unlikely to be able to transmit the virus to another person.

WHO has published an Emergency Global Supply Chain System (COVID-19) catalogue. This catalogue lists all medical devices, including personal protective equipment, medical equipment, medical consumables, single use devices, laboratory and test-related devices that may be requested through the COVID-19 Supply Portal.

.....
.....

Emergencies

Ebola – DRC+

Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 97: 16 June 2020

[Excerpts]

Situation Update

In Ituri, North Kivu and South Kivu provinces of the Democratic Republic of the Congo, no new confirmed cases of EVD have been reported since 27 April 2020.

From 8 to 14 June 2020, an average of 2975 alerts were reported and investigated each day. Of these, an average of 274 alerts were validated as suspected cases each day, requiring specialized care and laboratory testing to rule out EVD. In the past week, there have been a stable number of daily alerts reported throughout active sub-coordinations. Timely testing of suspected cases continues to be provided from eight laboratories. From 8 to 14 June 2020, 3219 samples were tested, including 2513 blood samples from alive, suspected cases; 324 swabs from community deaths; and 382 from re-tested patients. None of them tested positive.

The number of samples tested by the laboratories increased by 3% compared to the previous week...

Conclusions

Investigations into the origin of the last cluster of cases in Beni Health Zone are ongoing in collaboration with the Institut National de Recherche Biomédicale. There are challenges in EVD response activities due to limited resources given the other local and global emergencies. Maintaining a robust surveillance system in order to detect, isolate, test and treat new suspected cases as early as possible remains crucial. Continued coordination, communication among partners, authorities and communities along with EVD survivor advocacy are also essential.

.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 16 June 2020

Summary of new viruses this week (AFP cases and ES positives):

:: Afghanistan: four WPV1 cases, two WPV1 and three cVDPV2 positive environmental samples

:: Pakistan: one WPV1 case, 18 WPV1 positive environmental samples and two cVDPV2 cases

:: Côte d'Ivoire: three cVDPV2 cases and two cVDPV2 positive environmental samples

:: Somalia: four cVDPV2 positive environmental samples

.....
.....

WHO Grade 3 Emergencies [to 20 June 2020]

Democratic Republic of the Congo

:: Ebola Outbreak in DRC 97: 16 June 2020

[See Ebola above for detail]

Syrian Arab Republic

WHO airlifts over 80 tons of emergency medical supplies from Iraq to meet increasing health needs in northeast Syria

14 June 2020 – The World Health Organization (WHO) has dispatched more than 80 tons of urgently needed emergency medical supplies to support the health system in northeast Syria. The 3-cargo consignment was airlifted from Erbil in the Kurdistan region of Iraq to Damascus from 10 to 12 June...

Nigeria - *No new digest announcements identified*

Somalia - *No new digest announcements identified*

South Sudan - *No new digest announcements identified*

Yemen - *No new digest announcements identified*

.....

WHO Grade 2 Emergencies [to 20 June 2020]

Iraq

:: WHO airlifts over 80 tons of emergency medical supplies from Iraq to meet increasing health needs in northeast Syria

14 June 2020 – The World Health Organization (WHO) has dispatched more than 80 tons of urgently needed emergency medical supplies to support the health system in northeast Syria. The 3-cargo consignment was airlifted from Erbil in the Kurdistan region of Iraq to Damascus from 10 to 12 June...

Angola - *No new digest announcements identified*

Afghanistan - *No new digest announcements identified*

Burkina Faso [in French] - *No new digest announcements identified*

Burundi - *No new digest announcements identified*

Cameroon - *No new digest announcements identified*

Central African Republic - *No new digest announcements identified*

Ethiopia - *No new digest announcements identified*

Libya - *No new digest announcements identified*

Malawi - *No new digest announcements identified*

Measles in Europe - *No new digest announcements identified*

MERS-CoV - *No new digest announcements identified*

Myanmar - *No new digest announcements identified*

Niger - *No new digest announcements identified*

occupied Palestinian territory - *No new digest announcements identified*

Sudan - *No new digest announcements identified*

Ukraine - *No new digest announcements identified*

Zimbabwe - *No new digest announcements identified*

.....

WHO Grade 1 Emergencies [to 20 June 2020]

Chad - *No new digest announcements identified*

Djibouti – *Page not responding at inquiry*

Kenya - *No new digest announcements identified*

Mali - *No new digest announcements identified*

Namibia - viral hepatitis - *No new digest announcements identified*

Tanzania - *No new digest announcements identified*

.....

.....

UN OCHA – L3 Emergencies

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic

:: Syrian Arab Republic: COVID-19 Response Update No. 06 - 19 June 2020

Yemen

:: 18 June 2020 Yemen: COVID-19 Preparedness and Response Monthly Report (May 2020)

.....

UN OCHA – Corporate Emergencies

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

CYCLONE IDAI and Kenneth - *No new digest announcements identified*

EBOLA OUTBREAK IN THE DRC - *No new digest announcements identified*

.....

.....

WHO & Regional Offices [to 20 June 2020]

18 June 2020 *News release*

Countries failing to prevent violence against children, agencies warn

Global status report on preventing violence against children calls for more government action and warns of 'dramatic impact' of COVID-19

18 June 2020 *News release*

Luxembourg and WHO sign new Memorandum of Understanding, committing flexible funding to support WHO Triple billion targets

16 June 2020 *News release*

WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients

The World Health Organization (WHO) welcomes the initial clinical trial results from the United Kingdom (UK) that show dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. For patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth, according to preliminary findings shared with WHO.

The benefit was only seen in patients seriously ill with COVID-19, and was not observed in patients with milder disease...

13 June 2020 *News release*

A cluster of COVID-19 in Beijing, People's Republic of China

.....

Weekly Epidemiological Record, 19 June 2020, vol. 95, 25 (pp. 265–280)

Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Africa's wild polio-free status to be determined in August 9 June 2020

:: WHO concerned over COVID-19 impact on women, girls in Africa 18 June 2020

Humanitarian crises, including health emergencies affect men and women differently. As COVID-19 continues to spread in Africa, there are concerns over its impact on women and girls, with vulnerabilities feared to worsen as the pandemic overwhelms health systems.

WHO Region of the Americas PAHO

No new digest content identified.

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: Tapping into WHO expertise allows Uzbekistan to increase COVID-19 testing 19-06-2020

:: Expert networks scale up COVID-19 testing, tracing and treating in Tajikistan 19-06-2020

:: Stories of hope as refugees help tackle the COVID-19 pandemic 19-06-2020

:: Refugee nurse Ahmed Ahmed: working together to prevent COVID-19 infections in Turkey 19-06-2020

:: COVID-19: Preparing for the autumn is a priority for WHO/Europe 18-06-2020

WHO Eastern Mediterranean Region EMRO

:: UN and partners launch guidelines to address the needs of most vulnerable groups during COVID-19

Cairo, 15 June 2020 - Vulnerable groups, particularly women, displaced people, migrants, older persons and people with disabilities, may experience the most harmful impacts of COVID-19. This is due to many factors including discrimination and stigma, their exclusion from effective surveillance and early-warning systems as well as their limited access to primary healthcare services. Their particular needs must be...

WHO Western Pacific Region

No new digest content identified.

.....
.....

CDC/ACIP [to 20 June 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases

[CDC releases consolidated COVID-19 testing recommendations](#)

Saturday, June 13, 2020.

[MMWR News Synopsis Friday, June 19, 2020](#)

Progress Toward Rubella Elimination — Western Pacific Region, 2000–2019

Public Attitudes, Behaviors, and Beliefs Related to COVID-19, Stay-at-Home Orders, Nonessential Business Closures, and Public Health Guidance — United States, New York City, and Los Angeles, May 5–12, 2020 (Early release June 12, 2020)

Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 (Early release June 15, 2020)

.....

Africa CDC [to 20 June 2020]

<http://www.africacdc.org/>

News

Outbreak Brief 22: COVID-19 Pandemic – 16 June 2020

...As of 9 am EAT 16 June 2020, a total of 251,866 COVID-19 cases and 6,769 (CFR: 2.7%) deaths have been reported in 54 African countries. This is about 3.2% of all cases reported globally. Since the last brief (9 June 2020), 55,612 new COVID-19 cases have been reported, which is a 27% increase in new cases reported compared to what was reported in the previous week (2-9 June 2020)...

.....

China CDC

<http://www.chinacdc.cn/en/>

No new digest content identified.

National Health Commission of the People's Republic of China

<http://en.nhc.gov.cn/>

News

June 20: Daily briefing on novel coronavirus cases in China

2020-06-20

On June 19, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 27 new cases of confirmed infections (4 imported cases, 3 in Guangdong province and 1 in Shanghai municipality; 23 indigenous cases, 22 in Beijing municipality and 1 in Hebei province), 4 new cases of suspected infections (all are indigenous cases in Beijing), and no deaths. 12 patients were released from hospital after being cured. 232 people who had had close contact with infected patients were freed from medical observation. The number of serious cases remained unchanged...

Beijing hospital increasing beds to prepare for patients

2020-06-20

So far 183 cases have been confirmed in the capital since outbreak at market

Beijing Ditan Hospital has expanded its medical facility to 1,070 beds to prepare for COVID-19 cases, and professionals from other provinces will come to aid future investigation and analysis, the deputy head of the hospital said on June 19.

As a designated medical facility for novel coronavirus patients in Beijing, Ditan Hospital has received 183 patients, including two in critical condition and 11 with severe symptoms as of Thursday...

Chinese official urges relentless efforts to stem virus spread

2020-06-20

Beijing's outbreak data shared with world

2020-06-20

Chinese researchers have published data collected from samples of the coronavirus that caused the latest COVID-19 outbreak in Beijing and shared it with international organizations.

.....
.....

Announcements

Paul G. Allen Frontiers Group [to 20 June 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA [to 20 June 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

June 19, 2020

BARDA and Empatica forge new partnership to develop an early monitoring platform to identify COVID-19 infection

June 16, 2020

BARDA and Immunexpress Inc. expand partnership to evaluate a sepsis host-based laboratory diagnostic to triage COVID-19 patients

BMGF - Gates Foundation [to 20 June 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 20 June 2020]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 20 June 2020]

<https://carb-x.org/>

CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

06.17.2020

CARB-X funds Module Innovations to develop a simple test to diagnose urinary tract infections (UTI) and identify superbugs causing the infection within 2 hours

CARB-X is awarding Module Innovations of Pune, India, up to US\$702,000 plus up to \$2.5 million more if certain project milestones are met, to develop a rapid diagnostic for drug-resistant urinary tract infections (UTI) infections.

CEPI – Coalition for Epidemic Preparedness Innovations [to 20 June 2020]

<http://cepi.net/>

Latest News

No new digest content identified.

Clinton Health Access Initiative, Inc. (CHAI) [to 20 June 2020]

<https://clintonhealthaccess.org/>

News & Press Releases

No new digest content identified.

EDCTP [to 20 June 2020]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Latest news

No new digest content identified.

Emory Vaccine Center [to 20 June 2020]

<http://www.vaccines.emory.edu/>

No new digest content identified.

European Medicines Agency [to 20 June 2020]

<http://www.ema.europa.eu/ema/>

News & Press Releases

Press release: International regulators stress value of safe and effective vaccines

Last updated: 18/06/2020

News: Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #4

Last updated: 15/06/2020

European Vaccine Initiative [to 20 June 2020]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

FDA [to 20 June 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements

[June 19, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 19, 2020](#)

[June 18, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 18, 2020](#)

[June 18, 2020 - Coronavirus \(COVID-19\) Update: FDA Takes Additional Action to Harness Real-World Data to Inform COVID-19 Response Efforts](#)

[June 17, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 17, 2020](#)

[June 17, 2020 - Coronavirus \(COVID-19\) Update: FDA Issues Warning Letters to Companies Inappropriately Marketing Antibody Tests, Potentially Placing Public Health at Risk](#)

[June 16, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 16, 2020](#)

[June 16, 2020 - Coronavirus \(COVID-19\) Update: Facilitating Diagnostic Test Availability for Asymptomatic Testing and Sample Pooling](#)

[June 16, 2020 - Coronavirus \(COVID-19\) Update: FDA Revokes Emergency Use Authorization for Chembio Antibody Test](#)

[June 15, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 15, 2020](#)

[June 15, 2020 - Coronavirus \(COVID-19\) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use](#)

[June 15, 2020 - Coronavirus \(COVID-19\) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine](#)

Fondation Merieux [to 20 June 2020]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 20 June 2020]

<https://www.gavi.org/>

News releases

16 June 2020

[Pneumonia vaccine price drops dramatically for lower-income countries thanks to the Gavi Pneumococcal AMC](#)

GHIT Fund [to 20 June 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.*

Global Fund [to 20 June 2020]

<https://www.theglobalfund.org/en/news/>

Feature Story

[The Fight Against HIV, TB and Malaria Continues](#)

18 June 2020

Video

[The Fight Continues Against HIV](#)

18 June 2020

Updates

[Removing Human Rights Barriers to Health: Findings and Lessons](#)

15 June 2020

Hilleman Laboratories [to 20 June 2020]

<http://www.hillemanlabs.org/>

No new digest content identified.

Human Vaccines Project [to 20 June 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

No new digest content identified.

IAVI [to 20 June 2020]

<https://www.iavi.org/newsroom>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases

World Leaders Pledge US\$ 926 Million to IFFIm

15 Jun 2020

:: Italy, the Netherlands, Norway and Spain have renewed their support for IFFIm's innovative financing mechanism

:: Commitments to IFFIm are part of US\$ 8.8 billion in total pledges to Gavi

:: These new pledges will help Gavi immunise another 300 million children during the 2021-2025 period and respond to the COVID-19 crisis

IFRC [to 20 June 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Middle East and North Africa

COVID-19: Red Cross and Red Crescent urge more support for displaced people in the Middle East North Africa region

Beirut, 19 June 2020 – Ahead of World Refugee Day on 20 June, the International Federation of Red Cross and Red Crescent Societies (IFRC) is increasingly concerned that migrants, refugees and internally displaced people are falling through the cracks. ...

19 June 2020

World Refugee Day: New research demonstrates dramatic impact of COVID-19 on vulnerable refugees

Geneva, 19 June 2020 – New research released ahead of World Refugee Day demonstrates the considerable socio-economic impact that COVID-19 has had on already vulnerable refugees. The Red Cross and Red Crescent research focused on refugees living in Turk ...

19 June 2020

IVAC [to 20 June 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates

No new digest content identified.

IVI [to 20 June 2020]

<http://www.ivi.int/>

Selected IVI News & Announcements

No new digest content identified.

JEE Alliance [to 20 June 2020]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

MSF/Médecins Sans Frontières [to 20 June 2020]

<http://www.msf.org/>

Latest [Selected Announcements]

Coronavirus COVID-19 pandemic

[MSF opens 100-bed COVID-19 treatment centre in Bihar, India](#)

Press Release 19 Jun 2020

Refugees, IDPs and people on the move

["No one chooses to be a refugee"](#)

Voices from the Field 19 Jun 2020

Coronavirus COVID-19 pandemic

[Brazil's COVID-19 nightmare is far from under control](#)

Project Update 17 Jun 2020

-

Coronavirus COVID-19 pandemic

[Escaping first Libya, and then coronavirus in Germany](#)

Voices from the Field 15 Jun 2020

Afghanistan

[MSF withdraws from Dasht-e-Barchi following attack on patients and staff](#)

Press Release 15 Jun 2020

National Vaccine Program Office - U.S. HHS [to 20 June 2020]

<https://www.hhs.gov/vaccines/about/index.html>

NVAC 2020 Meetings

[September 23-24, 2020 Meeting \(Virtual\)](#)

NIH [to 20 June 2020]

<http://www.nih.gov/news-events/news-releases>

Selected News Releases

[NIH halts clinical trial of hydroxychloroquine](#)

June 20, 2020 — Study shows treatment does no harm, but provides no benefit

A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by the National Institutes of Health. A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19. After its fourth interim analysis the DSMB, which

regularly monitors the trial, recommended to the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to stop the study. NHLBI halted the trial immediately.

The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, was being conducted by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of NHLBI. The data from this study indicate that this drug provided no additional benefit compared to placebo control for the treatment of COVID-19 in hospitalized patients...

All of Us Research Program launches COVID-19 research initiatives

June 16, 2020 — NIH effort expands data collection to shed light on pandemic's spread and impact.

NIH launches analytics platform to harness nationwide COVID-19 patient data to speed treatments

June 15, 2020 — Effort aims to transform clinical information into knowledge urgently needed to study the novel coronavirus.

PATH [to 20 June 2020]

<https://www.path.org/media-center/>

Selected Announcements

PATH congratulates Serum Institute on Advance Market Commitment award for pneumococcal vaccine supply

June 18, 2020 by PATH

New supply agreement opens the door for pneumonia and other pneumococcal disease prevention to be more affordable and accessible for the world's most resource-strapped countries.

Sabin Vaccine Institute [to 20 June 2020]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

Sabin Vaccine Institute's Boost Community Prepares Immunization Professionals to Lead During the COVID-19 Crisis

Tuesday, June 16, 2020

WASHINGTON, D.C. – Amid the evolving global challenges posed by the novel coronavirus pandemic, immunization professionals must now grapple with deploying routine immunization services in a daunting and ever-shifting landscape. In a recent survey of 800 immunization professionals conducted by the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) and other key partners, 64 percent of respondents reported significant disruptions to immunization in their country or community, with either zero or limited outreach activities taking place and fewer visits to vaccination posts. To strengthen immunization professionals' ability to navigate the complex challenges of their work, Sabin launched the [Boost Community](#) (Boost), a global network dedicated to serving immunization professionals, supported by a grant from the Bill & Melinda Gates Foundation...

UNAIDS [to 20 June 2020]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

19 June 2020

[UNAIDS helps response to food insecurity during COVID-19 outbreak in Angola](#)

18 June 2020

[Local skills and knowledge help Senegalese community-led organizations deliver](#)

17 June 2020

[Remembering human rights activist Yves Yomb](#)

16 June 2020

[Online games fighting HIV stigma and discrimination in the Islamic Republic of Iran](#)

15 June 2020

[UNAIDS highlights six critical actions to put gender equality at the centre of COVID-19 responses](#)

15 June 2020

[New online resource for mental health services for key populations in Kazakhstan](#)

UNICEF [to 20 June 2020]

<https://www.unicef.org/media/press-releases>

Selected Press releases/Announcements

Press release

[UNICEF Cryptocurrency Fund announces its largest investment of startups in developing and emerging economies](#)

Among the awardees are companies expanding work to use their technologies to mitigate the hardships of COVID-19 on children and youth

Press release

18/06/2020

[UNICEF airlifts COVID-19 testing kits to Yemen to boost response as cases soar](#)

Press release

17/06/2020

[Countries failing to prevent violence against children, agencies warn](#)

Global status report on preventing violence against children calls for more government action and warns of 'dramatic impact' of COVID-19

Press release

16/06/2020

[Universal child benefits critical in reducing poverty, new ODI and UNICEF report finds](#)

As the economic fallout of COVID-19 deepens, investment in social protection systems key to protecting families from catastrophic levels of deprivation and financial hardship

Press release

16/06/2020

Pneumonia vaccine price drops dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment

New supply agreement between UNICEF and Serum Institute of India (SII) makes pneumococcal conjugate vaccine (PCV) available at US\$2.00 per dose, a 43 per cent reduction from the Gavi price at the start of the Advance Market Commitment

Unitaid [to 20 June 2020]

<https://unitaid.org/>

Featured News

19 June 2020

Unitaid commits further \$35 million for COVID-19 response

Geneva – New funding of up to US\$ 35 million has been approved by Unitaid's Executive Board to support the organisation's role in the 'test, treat and prevent' response to COVID-19.

This key decision was taken at the Board's meeting of 17-18 June 2020, and recognising Unitaid's role in the 'Access to COVID-19 Tools' (ACT) Accelerator partnership for development and availability of vaccines, therapeutics and diagnostics for COVID-19. This comes on top of US\$ 30 million already agreed in March 2020 as part of the COVID-19 response.

This decision comes in the context of the additional funding needs for the ACT-Accelerator work. Unitaid has identified a total of US\$265 million for its proposed work in the therapeutics, diagnostics and access areas.

The Board's action on a second tranche of funding will allow Unitaid to move fast to support needs identified by the ACT-Accelerator, in key areas like research and development of promising therapies, development and scale-up of rapid diagnostic tests adapted for low- and middle-income countries, as well as ensuring affordability and supporting health systems...

Vaccination Acceptance Research Network (VARN) [to 20 June 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 20 June 2020]

<http://www.vaccineconfidence.org/>

Latest News & Archive

[Undated]

Launching a new global initiative: Public sentiments and emotions around COVID-19 – What is the world feeling and how is it different across time and place?

The Vaccine Confidence Project is conducting a global study to track public sentiment and emotions around current and potential measures to contain and treat COVID-19. Through a mix of population surveys and social media monitoring and analysis over time and place, this year-long global study will investigate perception and sentiment of COVID-19 social distancing measures and potential medical tools globally...

Vaccine Education Center – Children’s Hospital of Philadelphia [to 20 June 2020]
<http://www.chop.edu/centers-programs/vaccine-education-center>
No new digest content identified.

Wellcome Trust [to 20 June 2020]
<https://wellcome.ac.uk/news>
Explainer | 15 June 2020

We need COVID-19 treatments as well as vaccines – and they have to work for everyone

Effective treatments, that are accessible to everyone who needs them, have to be part of the solution to the coronavirus pandemic – here's why.

The Wistar Institute [to 20 June 2020]
<https://www.wistar.org/news/press-releases>
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 20 June 2020]
<https://www.wfpha.org/>
Latest News

WFPHA Statement on Racism

Wednesday, 17 June 2020

Since its inception in 1967, social justice, equity and human rights have been the enduring values of the World Federation of Public Health...

World Organisation for Animal Health (OIE) [to 20 June 2020]
<https://www.oie.int/en/for-the-media/press-releases/2020/>
Press Releases

19/06/20

Maintaining efforts to fight animal diseases in times of COVID-19

As the world faces the consequences of the COVID-19 pandemic, the OIE calls countries to continue to implement prevention and control measures for animal diseases. Sustaining veterinary activities is essential to avoid the detrimental impacts of animal diseases, which could exacerbate the current sanitary and socio-economic crises. The main conclusions of the OIE report on the global animal health situation are presented

[Report on the current animal health situation worldwide: analysis of events and trends](#)

18/06/20

Overview of the activities of the OIE Specialist Commissions

16/06/20

New official disease status and control programmes recognised by the OIE

.....

ARM [Alliance for Regenerative Medicine] [to 20 June 2020]

<https://alliancerm.org/press-releases/>

Press Releases

No new digest content identified.

BIO [to 20 June 2020]

<https://www.bio.org/press-releases>

Press Releases

BIO's Dr. McMurry-Heath Calls Congressional Hearing "Important Step" to Addressing Covid-19 Health Disparities

June 17, 2020

BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement in advance of a congressional subcommittee hearing in the House Committee on Energy and Commerce on racial and ethnic disparities in Covid-19...

BIO Elects New Board Directors and Section Governing Board Chairs

June 16, 2020

The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee members for the 2020-2021 term. Additionally, eight new board directors and four new section governing board chairs and vice chairs...

DCVMN – Developing Country Vaccine Manufacturers Network [to 20 June 2020]

<http://www.dcvmn.org/>

News

No new digest content identified.

IFPMA [to 20 June 2020]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 20 June 2020]

<https://internationalbiotech.org/>

News

No new digest content identified.

PhRMA [to 20 June 2020]

<http://www.phrma.org/>

Selected Press Releases, Statements

No new digest content identified.

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control

June 2020 Volume 48, Issue 6, p591-732

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

June 2020 Volume 58, Issue 6, p757-898

<http://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

June 2020 110(6)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 102, Issue 6, June 2020

<http://www.ajtmh.org/content/journals/14761645/102/6>

[Reviewed earlier]

Annals of Internal Medicine

16 June 2020 Volume 172, Issue 12

<http://annals.org/aim/issue>

Ideas and Opinions

[A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19](#)

FREE

Alfred H.J. Kim, MD, PhD, Jeffrey A. Sparks, MD, MMSc, Jean W. Liew, MD, Michael S. Putman, MD, [... et al.](#)

Hydroxychloroquine, an essential treatment for many patients with rheumatologic conditions, has garnered widespread attention as a potential treatment for COVID-19 infection. The authors appraise the study generating this interest and highlight the potential consequences of rapid dissemination of overinterpreted data.

Artificial Intelligence – An International Journal

Volume 285 August 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/285/suppl/C>

Editorial Abstract only

Special issue on autonomous agents modelling other agents: Guest editorial

Stefano V. Albrecht, Peter Stone, Michael P. Wellman

Article 103292

Abstract

Much research in artificial intelligence is concerned with enabling autonomous agents to reason about various aspects of other agents (such as their beliefs, goals, plans, or decisions) and to utilise such reasoning for effective interaction. This special issue contains new technical contributions addressing open problems in autonomous agents modelling other agents, as well as research perspectives about current developments, challenges, and future directions.

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 20 June 2020)

[No new digest content identified]

BMJ Global Health

June 2020 - Volume 5 - 6

<https://gh.bmj.com/content/5/6>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 20 June 2020)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 20 June 2020)

Epidemiology, vaccine effectiveness, and risk factors for mortality for pneumococcal disease among hospitalised adults in Singapore: a case-control study

Streptococcus pneumoniae infections can lead to severe morbidity and mortality, especially in patients with invasive pneumococcal disease (IPD). This study evaluated factors associated with pneumococcal disease, ...

Authors: Tyson Chan, Min Zhi Tay, Win Mar Kyaw, Angela Chow and Hanley J. Ho

Citation: BMC Infectious Diseases 2020 20:423

Content type: Research article

Published on: 17 June 2020

Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?

The SARS-CoV-2, which emerged from East Asia in December 2019, has rapidly evolved into a global pandemic infecting close to 7 million people. The current uncertainties regarding its impact on Africa calls for...

Authors: Carlo Torti, Maria Mazzitelli, Enrico Maria Trecarichi and Owachi Darius

Citation: BMC Infectious Diseases 2020 20:412

Content type: Editorial

Published on: 15 June 2020

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 20 June 2020)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 20 June 2020)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 20 June 2020)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 20 June 2020)

Lay perspectives on social distancing and other official recommendations and regulations in the time of COVID-19: a qualitative study of social media posts

COVID-19 caused by a new form of coronavirus (SARS-CoV-2) first appeared in China end of 2019 and quickly spread to all counties of the world. To slow down the spread of the virus and to limit the pressure on ...

Authors: Sabahat Ölcer, Yüce Yilmaz-Aslan and Patrick Brzoska

Citation: BMC Public Health 2020 20:963

Content type: Research article

Published on: 19 June 2020

Trends in measles cases in Bayelsa state, Nigeria: a five-year review of case-based surveillance data (2014–2018)

Measles is a vaccine preventable, highly transmissible viral infection that affects mostly children under five years. It has been ear marked for elimination and Nigeria adopted the measles elimination strategi...

Authors: Neni Aworabhi-Okj, T. Numbere, M. S. Balogun, A. Usman, R. Utulu, N. Ebere, W. Omubo, J. Stow, S. Abba and A. Olorukooba

Citation: BMC Public Health 2020 20:938

Content type: Research article

Published on: 15 June 2020

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 20 June 2020)

[No new digest content identified]

BMJ Open

May 2020 - Volume 10 - 5

<https://bmjopen.bmj.com/content/10/6>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 98, Number 6, June 2020, 373-440

<https://www.who.int/bulletin/volumes/98/6/en/>

[Reviewed earlier]

Child Care, Health and Development

Volume 46, Issue 4 Pages: 397-536 July 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 107, Issue 6 Pages: 1263-1457 June 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/2020/107/6>

[Reviewed earlier]

Clinical Therapeutics

May 2020 Volume 42, Issue 5, p729-958, e87-e100

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 17 Issue 3, June 2020

<https://journals.sagepub.com/toc/ctja/17/3>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 20 June 2020]
[No new digest content identified]

Contemporary Clinical Trials

Volume 93 June 2020
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/93/suppl/C>
[New issue; No digest content identified]

The CRISPR Journal

Volume 3, Issue 3 / June 2020
<https://www.liebertpub.com/toc/crispr/3/3>
Perspective Free

[What Do We \(Not\) Know About Global Views of Human Gene Editing? Insights and Blind Spots in the CRISPR Era](#)

Emily L. Howell, Shiyu Yang, Becca Beets, Dominique Brossard, Dietram A. Scheufele, and Michael A. Xenos

Pages:148–155

Published Online:17 June 2020

Abstract

As research on human applications of CRISPR advances, researchers, advisory bodies, and other stakeholder organizations continue calling for global public discourses and engagement to shape the development of human gene editing (HGE). Research that captures public views and tests ways for engaging across viewpoints is vital for facilitating these discourses. Unfortunately, such research lags behind advances in HGE research and applications. Here, we provide the first review of nationally representative public-opinion surveys focused on HGE to discuss limitations and remaining gaps, illustrating how these gaps hinder interpretation of existing studies. Rigorous research with proper methods for capturing representative public opinion of HGE is limited, especially in countries outside of the United States and on a global scale. The result is severely restricted understanding of even the surface level of public views concerning HGE. We identify broad areas where we need more and better research capturing public views, and describe how future surveys can help collect insights necessary for discourse and decision making on HGE.

Current Genetic Medicine Reports

Volume 8, Issue 2, June 2020
<https://link.springer.com/journal/40142/8/2>
[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2020 - Volume 33 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Developing World Bioethics

Volume 20, Issue 1 Pages: 1-60 March 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 30, Issue 3, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 44, Issue 3 Pages: 433-618 July 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 21 Issue 6 4 June 2020

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 26, Number 6—June 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 31 June 2020

<https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 42, Issue 3 Pages: 1-44 May–June 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

Perspectives of minors and parents • Non-English speakers • Covid-19 and other infectious diseases

[Reviewed earlier]

The European Journal of Public Health

Volume 30, Issue 3, June 2020

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 20 June 2020]

Research Article metrics AWAITING PEER REVIEW

[COVID-19: Identifying countries with indicators of success in responding to the outbreak](#) [version 1; peer review: awaiting peer review]

David S. Kennedy, VK Vu, Hannah Ritchie, Rebecca Bartlein, Oliver Rothschild, Daniel G. Bausch, Max Roser, Anna C. Seale

Peer Reviewers Invited

PUBLISHED 18 Jun 2020

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 20 June 2020]

[No new digest content identified]

Global Health Action

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

2020 | Volume 8 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 15, 2020 Issue 7

<http://www.tandfonline.com/toc/rgph20/current>

Article

Protecting health during COVID-19 and beyond: A global examination of paid sick leave design in 193 countries*

Jody Heymann, Amy Raub, Willetta Waisath, Michael McCormack, Ross Weistroffer, Gonzalo Moreno, Elizabeth Wong & Alison Earle

Pages: 925-934

Published online: 12 May 2020

Article Commentary

COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment

Sriram Shamasunder, Seth M. Holmes, Tinashe Goronga, Hector Carrasco, Elyse Katz, Raphael Frankfurter & Salmaan Keshavjee

Pages: 1083-1089

Published online: 30 Apr 2020

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 20 June 2020]

[No new digest content identified]

Health Affairs

Vol. 39, No. 6 June 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

Rural Health, Behavioral Health & More

[Reviewed earlier]

Health and Human Rights

<https://www.hhrjournal.org/>

[Accessed 20 June 2020]

Papers-in-Press

[No new digest content identified]

Health Economics, Policy and Law

Volume 15 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 35, Issue 5, June 2020

<https://academic.oup.com/heapol/issue/35/5>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 20 June 2020]

[No new digest content identified]

Human Gene Therapy

Volume 31, Issue 11-12 / June 2020

<https://www.liebertpub.com/toc/hum/31/11-12>

Commentary Free

The Impact of the COVID-19 Pandemic on the Biotech Industry

Philip Reilly

Pages:608–609

Published Online:18 May 2020

... In 2021, the biotech sector will have a valuation at or above the valuation it had in late 2019. Preclinical work will be robust. Clinical trials will be near the volume of a year earlier. The regulatory review of clinical trials will be more efficient. New biotech companies will raise needed capital, and the number of new IPOs will not be much different than in 2019. There will be an uptick in M&A activity as large pharmaceutical companies acquire smaller companies (for example, the decision announced by Alexion on May 5 that it would acquire Portola at a valuation much below that company's value in mid-2019). Most important, the contributions of talented scientists both inside academe and in the industry will continue to initiate discovery programs, many of which will lead to new drugs in our endless battle against disease.

Humanitarian Exchange Magazine

Number 77, March 2020

<https://odihpn.org/magazine/responding-to-ebola-in-the-democratic-republic-of-congo/>

Responding to Ebola in the Democratic Republic of Congo

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families.

Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 16, Issue 5, 2020

<http://www.tandfonline.com/toc/khvi20/current>

Special Issue: Vaccine Acceptance

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 20 June 2020]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 20 June 2020]

[Mozambique's response to cyclone Idai: how collaboration and surveillance with water, sanitation and hygiene \(WASH\) interventions were used to control a cholera epidemic](#)

Cyclone Idai, which hit Mozambique in March 2019, was one of the worst climate-related natural disasters on record in the Southern Hemisphere causing massive destruction of housing and disruption to vital infr...

Authors: Joaquim Domingos Lequechane, Arlete Mahumane, Falume Chale, Crescêncio Nhabomba, Cristolde Salomão, Clemente Lameira, Sérgio Chicumbe and Cynthia Semá Baltazar

Citation: Infectious Diseases of Poverty 2020 9:68

Content type: Letter to the Editor

Published on: 16 June 2020

International Health

Volume 12, Issue 3, May 2020,
<https://academic.oup.com/inthealth/issue/12/3>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 7, No 5 (2020) May 2020
<https://www.ijcmph.com/index.php/ijcmph/issue/view/62>
[Reviewed earlier]

International Journal of Epidemiology

Volume 49, Issue Supplement_1, April 2020
https://academic.oup.com/ije/issue/49/Supplement_1
Big Data, Small Area
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 13 Issue 3 2020
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2>
Table of Contents

[Patients' rights and professional conduct issues in hospitals' codes of ethics](#)

Ebru Saygili, Yucel Ozturkoglu

The purpose of this study is to explore the presence of ethical standards in the content of international hospitals codes of ethics disclosed in their websites.

International Journal of Infectious Diseases

June 2020 Volume 95, p1-480
[https://www.ijidonline.com/issue/S1201-9712\(20\)X0007-5](https://www.ijidonline.com/issue/S1201-9712(20)X0007-5)
Coronavirus (COVID-19) Collection

[Positive effects of COVID-19 control measures on influenza prevention](#)

Di Wu, Jianyun Lu, Yanhui Liu, Zhoubin Zhang, Lei Luo
p345–346
Published online: April 10, 2020

Perspective

[Can cholera 'hotspots' be converted to cholera 'coldspots' in cholera endemic countries? The Matlab, Bangladesh experience](#)

K. Zaman, Deok Ryun Kim, Mohammad Ali, Faisal Ahmmed, Justin Im, Md Taufiqul Islam, Ashraful Islam Khan, Md Yunus, Md Alfazal Khan, Florian Marks, Firdausi Qadri, Jerome Kim, John D. Clemens
p28–31
Published online: February 29, 2020

JAMA

June 9, 2020, Vol 323, No. 22, Pages 2231-2350
<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

Emergency Use Authorization of Remdesivir- The Need for a Transparent Distribution Process

Michael G. Ison, MD, MS; Cameron Wolfe, MBBS, MPH; Helen W. Boucher, MD

JAMA. 2020;323(23):2365-2366. doi:10.1001/jama.2020.8863

This Viewpoint reviews the FDA's May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug not otherwise available in the US and for which demand will likely exceed supply.

An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US

Colette DeJong, MD; Alice Hm Chen, MD, MPH; Bernard Lo, MD

free access has active quiz

JAMA. 2020;323(23):2367-2368. doi:10.1001/jama.2020.8914

This Viewpoint proposes ethical principles to guide allocation of scarce inpatient therapies for hospitalized COVID-19 patients to maximize patient benefit, mitigate disparities, and minimize clinician burden.

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic

Paul Starr, PhD

free access has multimedia has audio

JAMA. 2020;323(23):2369-2370. doi:10.1001/jama.2020.8573

This Viewpoint proposes implementing comparison groups for policy decisions, for example assessing disease transmission with alternative housing vs in-home isolation of individuals who test positive for coronavirus disease 2019 (COVID-19), or with different durations or cycles of school openings, to gather data that could make broader and future policy implementations more informed and effective.

[Audio Interview:](#) Coronavirus Q&A: Managing the Pandemic

Editorial

Randomized Clinical Trials and COVID-19 - Managing Expectations

Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA

JAMA Pediatrics

June 2020, Vol 174, No. 6, Pages 517-628

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

JBI Database of Systematic Review and Implementation Reports

June 2020 - Volume 18 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

EDITORIAL

COVID-19 and One Health: shifting the paradigm in how we think about health

Henley, Phaedra
JBI Evidence Synthesis. 18(6):1154-1155, June 2020.

Journal of Adolescent Health

June 2020 Volume 66, Issue 6, p635-766
[https://www.jahonline.org/issue/S1054-139X\(20\)X0004-8](https://www.jahonline.org/issue/S1054-139X(20)X0004-8)
[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 68 (2020)
<https://www.jair.org/index.php/jair>
[Reviewed earlier]

Journal of Community Health

Volume 45, Issue 3, June 2020
<https://link.springer.com/journal/10900/45/3>
[Reviewed earlier]

Journal of Development Economics

Volume 145 June 2020
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/145/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 15 Issue 3, July 2020
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2020 - Volume 74 - 6
<https://jech.bmj.com/content/74/6>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 13, Issue 2 Pages: 89-177 May 2020
<https://onlinelibrary.wiley.com/toc/17565391/current>
[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 31, Number 2, May 2020

<https://muse.jhu.edu/issue/42391>

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 22, Issue 3, June 2020

<https://link.springer.com/journal/10903/22/3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 18, 2020_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 221, Issue 10, 15 May 2020,

<https://academic.oup.com/jid/issue/221/10>

[Reviewed earlier]

Journal of Medical Ethics

June 2020 - Volume 46 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 7, Issue 2 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

June 2020 Volume 221, p1-268

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 20 June 2020]
[No new digest content identified]

Journal of Public Health Management & Practice

May/June 2020 - Volume 26 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 41, Issue 2, June 2020

<https://link.springer.com/journal/41271/41/2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2020 Volume 17 Issue 167

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 27, Issue 3, April 2020

<https://academic.oup.com/jtm/issue/27/3>

[Reviewed earlier]

Journal of Virology

June 2020; Volume 94, Issue 12

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jun 20, 2020 Volume 395 Number 10241 p1883-1948, e107-e111

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[**Global governance for COVID-19 vaccines**](#)

The Lancet

[See Milestones/Perspectives above for full text]

Comment

The right to health must guide responses to COVID-19

Dainius Pūras, Judith Bueno de Mesquita, Luisa Cabal, Allan Maleche, Benjamin Mason Mei

Articles

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M Kuderer, on behalf of the COVID-19 and Cancer Consortium

Interpretation

Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.

The Lancet Child & Adolescent Health

Jun 2020 Volume 4 Number 6 p407-478, e12-e16

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jun 2020 Volume 2 Number 6 e268-e330

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jun 2020 Volume 8 Number 6 e737-e857

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jun 2020 Volume 20 Number 6 p629-754, e116-e147

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jun 2020 Volume 5 Number 6 e297-e360

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jun 2020 Volume 8 Number 6 p527-646, e43-e54

<http://www.thelancet.com/journals/lanres/issue/current>

Comment

Influenza immunisation in pregnancy is efficacious and safe, but questions remain

Paul Loubet, Vassilis Tsatsaris, Odile Launay

Tackling two pandemics: a plea on World Tuberculosis Day

Tom Wingfield, Luis E Cuevas, Peter MacPherson, Kerry A Millington, S Bertel Squire

Articles

Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials

Saad B Omer, et al. for the BMGF Supported Maternal Influenza Immunization Trials

Investigators Group

Open Access

Maternal influenza immunisation can reduce morbidity and mortality associated with influenza infection in pregnant women and young infants. We aimed to determine the vaccine efficacy of maternal influenza immunisation against maternal and infant PCR-confirmed influenza, duration of protection, and the effect of gestational age at vaccination on vaccine efficacy, birth outcomes, and infant growth up to 6 months of age...

Interpretation

The assessment of efficacy for women vaccinated before 29 weeks gestational age might have been underpowered, because the point estimate suggests that there might be efficacy despite wide CIs. Estimates of efficacy against PCR-confirmed influenza and safety in terms of adverse birth outcomes should be incorporated into any further consideration of maternal influenza immunisation recommendations.

Maternal and Child Health Journal

Volume 24, Issue 6, June 2020

<https://link.springer.com/journal/10995/24/6>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 40 Issue 3, April 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 2 Pages: 223-617 June 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

Original Scholarship

Open Access

Can Social Policies Improve Health? A Systematic Review and Meta-Analysis of 38 Randomized Trials

EMILIE COURTIN, SOOYOUNG KIM, SHANSHAN SONG, WENYA YU, PETER MUENNIG

Pages: 297-371

First Published: 19 March 2020

Policy Points

:: Social policies might not only improve economic well-being, but also health. Health policy experts have therefore advocated for investments in social policies both to improve population health and potentially reduce health system costs.

:: Since the 1960s, a large number of social policies have been experimentally evaluated in the United States. Some of these experiments include health outcomes, providing a unique opportunity to inform evidence-based policymaking.

:: Our comprehensive review and meta-analysis of these experiments find suggestive evidence of health benefits associated with investments in early life, income support, and health insurance interventions. However, most studies were underpowered to detect health outcomes.

Nature

Volume 582 Issue 7812, 18 June 2020

http://www.nature.com/nature/current_issue.html

[New issue; No digest content identified]

Nature Biotechnology

Volume 38 Issue 6, June 2020

<https://www.nature.com/nbt/volumes/38/issues/6>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 20 June 2020)

[No new digest content identified]

Nature Genetics

Volume 52 Issue 6, June 2020

[Reviewed earlier]

Nature Medicine

Volume 26 Issue 6, June 2020

<https://www.nature.com/nm/volumes/26/issues/6>

Editorial | 04 June 2020

[It is not the time for science fiction](#)

Government officials who disseminate unsupported claims about the novel coronavirus undermine public trust in science and in the public-health efforts that are essential to bringing the COVID-19 pandemic under control.

World View | 07 May 2020

[Protect against market exclusivity in the fight against COVID-19](#)

Patents and other intellectual properties could slow down the scale-up and accessibility of treatments and vaccines against COVID-19.

Ellen 't Hoen

Perspective | 11 June 2020

Ten recommendations for supporting open pathogen genomic analysis in public health

To support progress in genomic epidemiology, a transparent, user-friendly approach is required.

Allison Black, Duncan R. MacCannell [...] & Trevor Bedford

Abstract

Increasingly, public-health agencies are using pathogen genomic sequence data to support surveillance and epidemiological investigations. As access to whole-genome sequencing has grown, greater amounts of molecular data have helped improve the ability to detect and track outbreaks of diseases such as COVID-19, investigate transmission chains and explore large-scale population dynamics, such as the spread of antibiotic resistance. However, the wide adoption of whole-genome sequencing also poses new challenges for public-health agencies that must adapt to support a new set of expertise, which means that the capacity to perform genomic data assembly and analysis has not expanded as widely as the adoption of sequencing itself. In this Perspective, we make recommendations for developing an accessible, unified informatic ecosystem to support pathogen genomic analysis in public-health agencies across income settings. We hope that the creation of this ecosystem will allow agencies to effectively and efficiently share data, workflows and analyses and thereby increase the reproducibility, accessibility and auditability of pathogen genomic analysis while also supporting agency autonomy.

Nature Reviews Genetics

Volume 21 Issue 6, June 2020

<https://www.nature.com/nrg/volumes/21/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 20 Issue 6, June 2020

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 19 Issue 6, June 2020

[Reviewed earlier]

New England Journal of Medicine

June 18, 2020 Vol. 382 No. 25

<http://www.nejm.org/toc/nejm/medical-journal>

Clinical Implications of Basic Research

Amplifying RNA Vaccine Development

Deborah H. Fuller, Ph.D., and Peter Berglund, Ph.D.

... With the emergence of the Covid-19 pandemic, an mRNA vaccine was the first to enter clinical trials, with the first volunteers receiving the vaccine within 10 weeks after the genetic sequence of SARS-CoV-2 was released (www.modernatx.com/modernas-work-potential-vaccine-against-covid-19. opens in new tab). Nucleic acid vaccines are now a major hope for solving this pandemic crisis. This comes as no surprise. From their earliest conception, nucleic acid vaccines were recognized as a possible solution for a rapid pandemic response. The need for only the sequence of a pathogen in order to generate the vaccine and its simplicity in manufacture have long been recognized as superpowers in nucleic acid vaccines with regard to the delivery of a rapid response to an emerging epidemic. The ability of self-amplifying RNA vaccines, and now trans-amplifying RNA vaccines, to provide amplified and durable production of antigen in vivo, coupled with potent inherent innate immune-stimulating properties, adds to these powers and may provide the dose-sparing (i.e., getting the same immune responses with smaller doses of vaccine) that will probably be needed to meet global demands. We can only hope that their deployment will render the Covid-19 pandemic crisis into a more manageable challenge, saving lives and decreasing morbidity.

Pediatrics

Jun 2020, 145 (6)

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

Pharmaceutics

Volume 12, Issue 5 (May 2020)

<https://www.mdpi.com/1999-4923/12/5>

[Reviewed earlier]

PharmacoEconomics

Volume 38, Issue 6, June 2020

<https://link.springer.com/journal/40273/38/6>

[No issue; No digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 20 June 2020)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 20 June 2020)

[**Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis**](#)

Giorgia Sulis, Pierrick Adam, Vaidehi Nafade, Genevieve Gore, Benjamin Daniels, Amrita Daftary, Jishnu Das, Sumanth Gandra, Madhukar Pai
Research Article | published 16 Jun 2020 PLOS Medicine
<https://doi.org/10.1371/journal.pmed.1003139>

[The potential impact of COVID-19 in refugee camps in Bangladesh and beyond: A modeling study](#)

Shaun Truelove, Orit Abraham, Chiara Altare, Stephen A. Lauer, Krya H. Grantz, Andrew S. Azman, Paul Spiegel
Research Article | published 16 Jun 2020 PLOS Medicine
<https://doi.org/10.1371/journal.pmed.1003144>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>
(Accessed 20 June 2020)

[Social marketing interventions for the prevention and control of neglected tropical diseases: A systematic review](#)

Nathaly Aya Pastrana, Maria Lazo-Porras, J. Jaime Miranda, David Beran, L. Suzanne Suggs
Research Article | published 17 Jun 2020 PLOS Neglected Tropical Diseases
<https://doi.org/10.1371/journal.pntd.0008360>

PLoS One

<http://www.plosone.org/>
[Accessed 20 June 2020]

[Recruiters' perspectives of recruiting women during pregnancy and childbirth to clinical trials: A qualitative evidence synthesis](#)

Vivienne Hanrahan, Katie Gillies, Linda Biesty
Research Article | published 19 Jun 2020 PLOS ONE
<https://doi.org/10.1371/journal.pone.0234783>

[Seasonal influenza vaccination in older people: A systematic review and meta-analysis of the determining factors](#)

George N. Okoli, Otto L. T. Lam, Florentin Racovitan, Viraj K. Reddy, Christiaan H. Righolt, Christine Neilson, Ayman Chit, Edward Thommes, Ahmed M. Abou-Setta, Salaheddin M. Mahmud
Research Article | published 18 Jun 2020 PLOS ONE
<https://doi.org/10.1371/journal.pone.0234702>

[A hidden vulnerable population: Young children up-to-date on vaccine series recommendations except influenza vaccines](#)

William K. Bleser, Daniel A. Salmon, Patricia Y. Miranda
Research Article | published 18 Jun 2020 PLOS ONE
<https://doi.org/10.1371/journal.pone.0234466>

[Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake](#)

Steven Brownstone, Alison Connor, Daniel Stein
Research Article | published 18 Jun 2020 PLOS ONE
<https://doi.org/10.1371/journal.pone.0233149>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 20 June 2020]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

[Economic and social consequences of human mobility restrictions under COVID-19](#)

Giovanni Bonaccorsi, Francesco Pierri, Matteo Cinelli, Andrea Flori, Alessandro Galeazzi, Francesco Porcelli, Ana Lucia Schmidt, Carlo Michele Valensise, Antonio Scala, Walter Quattrociocchi, and Fabio Pammolli
PNAS first published June 18, 2020. <https://doi.org/10.1073/pnas.2007658117>

[Vaccination as a social contract](#)

Lars Korn, Robert Böhm, Nicolas W. Meier, and Cornelia Betsch
PNAS first published June 15, 2020. <https://doi.org/10.1073/pnas.1919666117>

Prehospital & Disaster Medicine

Volume 35 - Issue 3 - June 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 135 June 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/135/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

10 June 2020 Volume 287 Issue 1928

<https://royalsocietypublishing.org/toc/rspb/current>
[No new digest content identified]

Public Health

Volume 183 Pages 1-152 (June 2020)

<https://www.sciencedirect.com/journal/public-health/vol/183/suppl/C>
[New issue; No digest content identified]

Public Health Ethics

Volume 12, Issue 3, November 2019

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 135 Issue 3, May/June 2020

<https://journals.sagepub.com/toc/phrg/135/3>

[Reviewed earlier]

Qualitative Health Research

Volume 30 Issue 7, June 2020

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 16 Issue 1-2, January-April 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 20 June 2020]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 40, Issue 6 Pages: 1111-1319 June 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

Original Research Articles

[Understanding Risk Information Seeking and Processing during an Infectious Disease Outbreak: The Case of Zika Virus](#)

Austin Y. Hubner, Shelly R. Hovick

Pages: 1212-1225

First Published: 17 February 2020

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 20 June 2020]

[No new digest content identified]

Science

19 June 2020 Vol 368, Issue 6497

<http://www.sciencemag.org/current.dtl>

In Depth

Pandemic vaccines are about to face the real test

By Jon Cohen

Science 19 Jun 2020 : 1295-1296 Full Access

U.S. and global efforts are taking different approaches to key efficacy trials of candidates.

Summary

A Chinese company will turn to Brazil for help. The World Health Organization is adopting a strategy forged in a war zone during an Ebola outbreak. And the Trump administration plans to lean on existing infrastructure for testing HIV and flu vaccines. These are the disparate strategies about to be employed in the next and most important stage of the COVID-19 vaccine race: the large-scale, placebo-controlled, human trials needed to prove which of the more than 135 candidates are safe and effective.

Science Translational Medicine

17 June 2020 Vol 12, Issue 548

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 253 May 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/253/suppl/C>

Research article Open access

Social, ethical, and other value judgments in health economics modelling

Stephanie Harvard, Gregory R. Werker, Diego S. Silva

Article 112975

Highlights

:: Interviews with health economists reinforced philosophical arguments positing a role for values throughout research.

:: Values informed early modelling decisions, model assumptions, and trade-offs between

:: Values played a role in assessing consequences of error and taking action under uncertainty in the modelling process.

Abstract

Modelling is a major method of inquiry in health economics. In other modelling-intensive fields, such as climate science, recent scholarship has described how social and ethical values influence model development. However, no similar work has been done in health economics. This study explored the role of social, ethical, and other values in health economics modelling using philosophical theory and qualitative interviews in British Columbia, Canada. Twenty-two

professionals working in health economics modelling were interviewed between February and May, 2019. The study findings provide support for four philosophical arguments positing an essential role for social and ethical values throughout scientific inquiry and demonstrate how these arguments apply to health economics modelling. It highlights the role of social values in informing early modelling decisions, shaping model assumptions, making trade-offs between desirable model features, and setting standards of evidence. These results point to several decisions in the modelling process that warrant focus in future health economics research, particularly that which aims to incorporate patient and public values.

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 20 June 2020]

[No digest content identified]

Travel Medicine and Infectious Diseases

Volume 35 May–June 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/35/suppl/C>

[New issue; No digest content identified]

Tropical Medicine & International Health

Volume 25, Issue 6 Pages: i-iv, 645-750 June 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28>

Conference info Abstract only

[Preparing to introduce new maternal immunizations in low- and lower-middle-income countries: A report from the Bill & Melinda Gates Foundation convening "Allies in Maternal and Newborn Care"; May 3–4, 2018](#)

Ajoke Sobanjo-ter Meulen, Jerker Liljestrand, Joy E. Lawn, Joachim Hombach, ... Keith P. Klugman

Pages 4355-4361

Discussion Open access

[Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019](#)

Sami L. Gottlieb, Francis Ndowa, Edward W. Hook, Carolyn Deal, ... Birgitte K. Giersing
Pages 4362-4373

Research article No access

[Electronic immunization registers – A tool for mitigating outbreaks of vaccine-preventable diseases in the Pacific](#)

Meru Sheel, Ashley Tippins, Kathryn Glass, Martyn Kirk, Colleen L. Lau
Pages 4395-4398

Research article Abstract only

Routine immunization coverage in Pakistan: a survey of children under 1 year of age in community-based vaccination areas

Meghana Sreevatsava, Ashley L. Burman, Ashraf Wahdan, Rana M. Safdar, ... Jamal Ahmed
Pages 4399-4404

Research article Abstract only

The contagious nature of a vaccine scare: How the introduction of HPV vaccination lifted and eroded MMR vaccination in Denmark

Mette Gørtz, Noel T. Brewer, Peter Reinhard Hansen, Mette Ejrnæs
Pages 4432-4439

Research article Abstract only

Immunizations at Wisconsin Pharmacies: Results of a statewide vaccine registry analysis and pharmacist survey

Philip C. Berce, Rebecca S. Bernstein, George E. MacKinnon, Sarah Sorum, ... Kenneth G. Schellhase
Pages 4448-4456

Special Section on "Future of Vaccine Development"; Edited by W. Koff and T. Schenkelberg

Research article Abstract only

The future of vaccine development

Wayne C. Koff, Theodore Schenkelberg
Pages 4485-4486

Abstract

Vaccines are one of the most successful public health interventions in our history resulting in eradication of small pox, near eradication of polio and major reductions in case number and global morbidity and mortality for numerous diseases (Centers for Disease C, 1999) [1]. However, vaccine development has been less successful against complex infectious diseases, where pathogen variability and/or immune evasion mechanisms have combined to pose major obstacles, and have been unsuccessful against non-communicable diseases, including cancer, autoimmunity, allergy, neurodegenerative and metabolic diseases (Koff et al., 2013) [2]. In addition, the current state of vaccine development is an expensive, slow and laborious process, costing billions of dollars, taking decades, with less than a 10% rate of success (Pronker et al., 2013) [3]. While some vaccines, such as the smallpox vaccine approach the gold standard of life-long protection in everyone following a single immunization, other vaccines are less effective, often requiring multiple immunizations, being less effective to populations most susceptible to disease such as infants, the elderly, and those living in the developing world. There is clearly an urgent need to determine ways to improve not just the effectiveness of the vaccines themselves but also the very processes by which they are developed.

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 20 June 2020)

Open Access Article

Trends, Coverage and Influencing Determinants of Influenza Vaccination in the Elderly: A Population-Based National Survey in Spain (2006–2017)

by Silvia Portero de la Cruz and Jesús Cebrino

Vaccines 2020, 8(2), 327; <https://doi.org/10.3390/vaccines8020327> - 19 Jun 2020

Abstract

Influenza is a significant public health problem and the elderly are at a greater risk of contracting the disease. The vaccination coverage of the elderly is below the Spanish target of 65% for each influenza season. The aims of this study were to report the coverage of influenza vaccination in Spain among the population aged ≥ 65 years and high-risk groups for suffering chronic diseases, to analyze the time trends from 2006 to 2017 and to identify the factors which affect vaccination coverage. A nationwide cross-sectional study was conducted including 20,753 non-institutionalized individuals aged ≥ 65 years who had participated in the Spanish National Health Surveys in 2006, 2011/2012, and 2017. Sociodemographic, health-related variables, and influenza vaccination data were used. A logistic regression analysis was performed to determine the variables associated with influenza vaccination. Influenza vaccination coverage was 60%. By chronic condition, older people with high cholesterol levels and cancer had the lowest vaccination coverage (62.41% and 60.73%, respectively). This coverage declined from 2006 to 2017 in both groups. Higher influenza vaccination was associated with males, Spanish nationality, normal social support perceived, polypharmacy, worse perceived health, participation in other preventive measures, and increasing age and the number of chronic diseases.

Value in Health

June 2020 Volume 23, Issue 6, p677-826

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0008-8](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0008-8)

ISPOR REPORT

Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group

Rachel L. Harrington, Maya L. Hanna, Elisabeth M. Oehrlein, Rob Camp, Russell Wheeler, Clarissa Cooblall, Theresa Tesoro, Amie M. Scott, Rainald von Gizycki, Francis Nguyen, Asha Hareendran, Donald L. Patrick, Eleanor M. Perfetto

p677–688

Published online: May 23, 2020

* * * *

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

No new digest content identified.

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 20 June 2020

[No new, unique, relevant content]

BBC

<http://www.bbc.co.uk/>

Accessed 20 June 2020

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 20 June 2020

Geopolitics

[The new world disorder](#)

If America pulls back from global institutions, other powers must step forward

Financial Times

<http://www.ft.com/home/uk>

Accessed 20 June 2020

Coronavirus treatment

[Europeans discuss deal to access potential J&J coronavirus vaccine](#)

European countries are lining up a deal to secure a possible Covid-19 vaccine from US company Johnson & Johnson, marking the latest move in an intensifying international battle to secure supplies of any coronavirus treatments that emerge.

Both the European Commission and a separate quartet of EU member states comprising Germany, France, Italy and the Netherlands have held talks with J&J as the world's largest healthcare company prepares to start clinical trials of its candidate next month, European diplomats said.

The contacts with J&J, first reported by Reuters, come after the European Commission unveiled a plan to spend billions of euros on advanced purchase deals with drugs businesses to obtain vaccine supplies for EU countries.

The growing efforts by rich nations including the US to strike such agreements has stoked fears that poorer nations will be squeezed out of access.

June 18, 2020

Forbes

<http://www.forbes.com/>

Accessed 20 June 2020

Jun 19, 2020

Immunity To Covid-19 Infection May Fade Quickly

A new study published in Nature Medicine indicates that immunity to infection by SARS-CoV-2 may fade quickly, at least in people with no or moderate symptoms.

By William A. Haseltine Contributor

Jun 18, 2020

Fauci Says He'll Oppose Any Rush To Unveil Coronavirus Vaccine In Trump's 'Operation Warp Speed'

"There is no chance in the world I'm going to be forced into agreeing to something that I don't think is safe and scientifically sound."

By Jemima McEvoy Contributor

Jun 16, 2020

9 Pharmaceutical Companies Racing For A COVID-19 Vaccine

Globally, there are more than 100 vaccines under development — with nine of them in human clinical trials already, asserts equity analyst Sel Hardy, in CFRA Research's flagship newsletter, The Outlook.

By MoneyShow Contributor

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 20 June 2020

[No new, unique, relevant content]

Foreign Policy

<http://foreignpolicy.com/>

Accessed 20 June 2020 | [No new, unique, relevant content]

[No new, unique, relevant content]

The Guardian

<http://www.guardiannews.com/>

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 20 June 2020

[No new, unique, relevant content]

New York Times

<http://www.nytimes.com/>

Accessed 20 June 2020

[No new, unique, relevant content]

Washington Post

<https://www.washingtonpost.com/>

Accessed 20 June 2020

Trump pushing officials to speed up already-ambitious coronavirus vaccine timeline

Yasmeen Abutaleb, Josh Dawsey, Laurie McGinley and Carolyn Y. Johnson

Jun 17, 2020

US expects insurers to cover COVID vaccine without copays

Jun 16, 2020

Germany to take stake in company working on virus vaccine [CureVac]

Jun 15, 2020

* * * *

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 20 June 2020

[No new relevant content]

Center for Global Development [to 20 June 2020]

<http://www.cgdev.org/page/press-center>

Accessed 20 June 2020

June 16, 2020

What Can Policymakers Learn about COVID-19 from Looking at Different Model Estimates?

Because of the uncertainties that complicate modelling, there is value in different research groups working independently to build models. Different models will employ different methods, data, and assumptions and will seek to answer different policy questions. Here we take a look from an end-user's perspective at what models can tell us, by looking for one example country, the Republic of South Africa.

[Y-Ling Chi](#), [Kalipso Chalkidou](#) and [Damian Walker](#)

June 15, 2020

Using Military Health Systems in the Response to COVID-19

COVID-19 has placed an unimaginable strain on health systems across the world, especially in regions that have been hit hardest. Some countries have utilised their armed forces to assist the civilian response to the COVID-19 crisis. Recognising the important relationship between the military and medical institutions this blog outlines how militaries around the world—but specifically in eight European countries—have been feeding into the COVID-19 response.

[Joseph Kazibwe](#) et al.

Chatham House [to 20 June 2020]

<https://www.chathamhouse.org/>

[No new relevant content]

CSIS

<https://www.csis.org/>

Accessed 20 June 2020

[No new relevant content]

Council on Foreign Relations

<http://www.cfr.org/>

Accessed 20 June 2020

June 15, 2020

United States

The State of U.S. Strategic Stockpiles

The coronavirus pandemic has renewed attention on the Strategic National Stockpile, the nation's emergency reserve of medical supplies. It's just one of the stockpiles the United States maintains for...

Backgrounder by [Anshu Siripurapu](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 20 June 2020

[No new relevant content]

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the [GE2P2 Global Foundation](#) – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine,

and an operating affiliation with the Vaccine Education Center of Children's Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*